PODD ALERT: Levi & Korsinsky Investigates Insulet Corporation on Behalf of Shareholders Who Lost Money
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-04-06 12:42 AM EDT
Investors in Disc Medicine, Inc. (IRON) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL...
2026-04-06 12:39 AM EDT
Investigation Opened on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA Biologics, Inc.") concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of...
2026-04-06 12:36 AM EDT
Potential Securities Fraud: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT)
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Freshpet, Inc. (NASDAQ: FRPT) ("Freshpet, Inc.") concerning potential violations of the federal securities laws. On March 17, 2026, an NAD ruling came through after a Fast-Track SWIFT challenge, an expedited single-issue process, was brought by one of Freshpet's competitors, The Farmer's Dog. The Farmer's Dog argued that three of Freshpet's video ads included...
2026-04-06 12:19 AM EDT
Investors in Immutep Limited (IMMP) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ:IMMP) ("Immutep Limited") concerning potential violations of the federal securities laws. On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative...
2026-04-06 12:12 AM EDT
Investors in Phreesia, Inc. (PHR) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - April 1, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Phreesia, Inc. ("Phreesia, Inc.") (NYSE: PHR) concerning potential violations of the federal securities laws. On December 8, 2025, CFO Balaji Gandhi told investors on the Q3 2026 earnings call: "For fiscal year 2027, we expect revenue to be in the range of $545 million to $559 million." Gandhi also stated that the recently acquired AccessOne would "contribute...
2026-04-01 11:45 AM EDT
Ongoing Securities Investigation into Freshpet, Inc. (FRPT) - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Freshpet, Inc. (NASDAQ: FRPT) ("Freshpet, Inc.") concerning potential violations of the federal securities laws. On March 17, 2026, an NAD ruling came through after a Fast-Track SWIFT challenge, an expedited single-issue process, was brought by one of Freshpet's competitors, The Farmer's Dog. The Farmer's Dog argued that three of Freshpet's video ads included...
2026-03-30 4:14 AM EDT
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Disc Medicine, Inc. (IRON)
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL...
2026-03-30 12:30 AM EDT
Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited ("Immutep Limited") (NASDAQ: IMMP) concerning potential violations of the federal securities laws. On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative...
2026-03-30 12:14 AM EDT
Did Aldeyra Therapeutics, Inc. (ALDX) Mislead Investors? Levi & Korsinsky Investigates
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review...
2026-03-30 12:12 AM EDT
Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of...
2026-03-30 12:10 AM EDT
ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-03-30 12:08 AM EDT
GOSS ALERT: Ongoing Investigation Into Gossamer Bio, Inc. - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient...
2026-03-30 12:06 AM EDT
Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review...
2026-03-27 3:38 PM EDT
Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of...
2026-03-27 11:50 AM EDT
Fraud Investigation Opened: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Freshpet, Inc. ("Freshpet, Inc.") (NASDAQ: FRPT) concerning potential violations of the federal securities laws. On March 17, 2026, an NAD ruling came through after a Fast-Track SWIFT challenge, an expedited single-issue process, was brought by one of Freshpet's competitors, The Farmer's Dog. The Farmer's Dog argued that three of Freshpet's video ads included...
2026-03-25 9:47 AM EDT
Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient...
2026-03-23 12:15 AM EDT
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL...
2026-03-23 12:13 AM EDT
Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ: IMMP) ("Immutep Limited") concerning potential violations of the federal securities laws. On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative...
2026-03-23 12:11 AM EDT
PODD ACTIVE INVESTIGATION: Lost Money on Insulet Corporation? Contact Levi & Korsinsky Now
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-03-23 12:08 AM EDT